Abstract
Opinion statement: Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.
Original language | English (US) |
---|---|
Pages (from-to) | 58-70 |
Number of pages | 13 |
Journal | Current treatment options in oncology |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2012 |
Externally published | Yes |
Keywords
- Recurrent salivary gland cancer
- Recurrent salivary gland neoplasm
- Salivary gland cancer
- Salivary gland neoplasm
- Salivary gland surgery
- Salivary gland tumor
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)